Status:
WITHDRAWN
Study of Pamidronate for the Prevention of Heterotopic Ossification
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborating Sponsors:
FAG (Freie Medizinische Gesellschaft)
Conditions:
Heterotopic Ossification
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
The purpose of this study is to determine whether Bisphosphonates in comparison to radiation therapy are effective in the prophylaxis and treatment of heterotopic ossification in high risk patients.
Detailed Description
BACKGROUND: The acquired form of heterotopic ossification (HO) is the most common type of extraskeletal ossification and usually precipitated by a trauma such as total hip arthroplasty \[THA\] or spin...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Consecutive patients with established HO (Brooker grade III-IV), hospitalized for resection of HO lesions
- Exclusion criteria:
- Age \<20 years
- Vitamin D deficiency (25OH-Vitamin D \<30 ng/ml)
- Renal insufficiency (Clearance \<50 ml/min)
- Intolerance of bisphosphonates
- Unable to provide informed consent
Exclusion
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00262392
Start Date
June 1 2005
End Date
June 1 2010
Last Update
March 10 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.